期刊文献+

首剂阿托伐他汀强化负荷对正常低密度脂蛋白心梗患者急诊PCI中无复流的作用 被引量:3

The effects of first intensive dose atorvastatin on no-reflow in acute myocardial infarction patients of normal LDL-C treated with percutaneous coronary intervention
下载PDF
导出
摘要 目的:观察术前负荷阿托伐他汀80mg的强化他汀治疗对于低密度脂蛋白(LDL-C)正常的急性ST段抬高心肌梗塞(STEAMI)患者行急诊经皮冠状动脉介入治疗(PCI)术中出现无复流风险的影响。方法:因STEAMI行急诊PCI治疗患者80例,入选患者的血脂LDL-C均正常;随机分为强化他汀组(强化组,n=40)及常规他汀组(常规组,n=40),强化组于手术当日术前给予阿托伐他汀首次剂量80mg预处理,1d后每日40mg,服2周,以后每日20mg长期服用;常规组手术当日于术前给予阿托伐他汀40mg,术后每日40mg,服2周,以后每日20mg长期服用;观察术中无复流的发生率。结果:两组均未出现明显不良反应。强化他汀组STEAMI患者行急诊PCI术中无复流的发生率为10%,常规他汀组无复流的发生率为22.5%,差异有统计学意义(P<0.05)。结论:急诊PCI术前首次给予80mg负荷剂量的阿托伐他汀能够降低LDL-C正常的急诊STEMI患者术中无复流的发生。 Objective:To observe the the effects of first dose 80 mg atorvastatin on no-reflow in ST-seg-ment elevation acute myocardial infarction patients of normal LDL-C treated with percutaneous coronary interven-tion .Methods:80 patients of normal LDL-C with STEAMI successfully treated with PCI were divided into the treat-ment group(40 patients )and the control group (40 patients ) .The treatment patients were given preoperative dose of atorvastatin 80 mg before the PCI ,40 mg daily after one day for 2 weeks ,20mg daily for long-term .The control pa-tients were given atorvastatin 40 mg before the PCI ,40 mg daily for 2 weeks ,20 mg daily for long-term .The inci-dence of no-reflow was observed .Results :There were no significant adverse reactions in the two groups .The treat-ment group of no-reflow incidence was 10% ,the control group of no-reflow was 22 .5% .The difference was statisti-cally significant (P〈0 .05) .Conclusion :First given 80 mg atorvastatin before PCI can reduce the incidence of no-re-flow with acute STEMI of normal LDL-C .
出处 《陕西医学杂志》 CAS 2014年第10期1362-1364,共3页 Shaanxi Medical Journal
基金 湖北省卫生厅青年人才基金项目(QJX-2012-24)
关键词 心肌梗塞 经皮冠状动脉介入治疗 脂蛋白类 .LDL 西司他汀类 心肌再灌注 Myocardial infarction Percutaneous coronary Intervention Lipoproteins,LDL. Cystatins Myocardial reperfusion
  • 相关文献

参考文献2

二级参考文献15

  • 1蒋晨阳,李楠,王建安.Use of B-type natriuretic peptide in evaluation of early percutaneous coronary intervention in patients with acute coronary syndrome[J].Chinese Medical Journal,2004(8):1130-1134. 被引量:17
  • 2张捷,贾珂珂,胡晓舟,崔丽艳.血清NT-proBNP和CRP水平对AMI后左室重构的预测价值[J].临床检验杂志,2006,24(2):91-93. 被引量:17
  • 3Kloner RA, Dai W. Glycoprotein Ⅱb/Ⅲa inhibitors and no-reflow[J]. J Am Coll Cardiol, 2004,43 : 284-286.
  • 4Reffelmann T, Kloner RA. Microvascular reperfusion injury: rapid expansion of anatomic no reflow during reperfusion in the rabbit[J]. Am J Physiol Heart Cire Physiol, 2002,283 : H1099-1107.
  • 5Koch KC, vom Dahl J, Kleinhans E, et al. Influence of a platelet GP Ⅱb/Ⅲa receptor antagonist on myocardial hypoperfusion during rotational atherectomy as assessed by myocardial Tc-99m sestamibi scintigraphy[J]. J Am Coll Cardiol, 1999,33 : 998-1004.
  • 6de Lemos JA, Antman EM, Gibson CM, et al. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial [J]. Circulation, 2000,101:239-243.
  • 7Parikh KH, Chag MC, Shah KJ, et al. Intracoronary boluses of adenosine and sodium nitroprusside in combination reverses slow/no-reflow during angioplasty: a clinical scenario of ischemic preconditioning [J]. Can J Physiol Pharmacol, 2007,85 : 476-482.
  • 8Warnholtz A, Ostad MA, Heitzer T, et al. Effect of tirofiban on percutaneous coronary intervention-induced endothelial dysfunction in patients with stable coronary artery disease[J]. Am J Cardiol, 2005,95:20-23.
  • 9Gamboa A, Shibao C, Diedrich A, et al. Contribution of endothelial nitric oxide to blood pressure in humans [J]. Hypertension, 2007,49:170-177.
  • 10Schulz R, Kelm M, Heusch G. Nitric oxide in myocardial ischemia/reperfusion injury[J]. Cardiovasc Res, 2004,61:402-413.

共引文献26

同被引文献38

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部